Golden Cross Appears Before Incyte Investors
If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called…
Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $77
Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $76 to $77.
Incyte Corporation Announces Late Wednesday Phase 3 Data Showing Improvements In Facial And Total Body Repigmentation With Ruxolitinib Cream In Vitiligo Published In New England Journal Of Medicine
Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older
Fifty-two
Analyst Thinks This Company’s Bone Marrow Cancer Treatment Can ‘Transform Paradigm’
SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ:CTIC) with an Outperform rating and a $13 price target. CTIC is a commercial-stage…
Death Cross Looms Over Incyte Investors
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
Evercore ISI Group Downgrades Incyte to In-Line, Lowers Price Target to $78
Evercore ISI Group analyst Maneka Mirchandaney downgrades Incyte (NASDAQ:INCY) from Outperform to In-Line and lowers the price target from $90 to $78.